Opinion|Videos|November 18, 2026

Rapid-Acting Antidepressants and the Psychedelics Debate

Rapid-acting options are reshaping expectations for how quickly depression treatment should work. The panel compares glutamatergic mechanisms across therapies and questions whether enthusiasm for psychedelics has outpaced the evidence behind them.

"Rapid-Acting Antidepressants and the Psychedelics Debate" takes up the newest rapid-acting options in depression care, from glutamatergic agents to psychedelics.

Dr. Citrome introduces the oral combination of dextromethorphan and bupropion as an accessible, ketamine-like rapid-acting option. Dr. Harding pushes back slightly on that framing but explains the mechanism: dextromethorphan acts as an NMDA receptor antagonist, thought to increase synaptic number and function, while bupropion's role is largely to inhibit the enzyme that would otherwise break dextromethorphan down, rather than acting through its usual pathway. She contrasts this daily dosing approach with the pulsatile dosing of ketamine and esketamine, delivered twice weekly for four weeks, where effects persist after the drug itself has cleared. She notes the STRIDE trial did not meet its efficacy endpoint for that combination in treatment-resistant depression, and that solid first-line data for ketamine in unipolar depression remain limited, making direct comparisons across these compounds difficult.

Still, she agrees rapid-acting agents have changed the field, pointing to trials, including a newer Alzheimer's agitation indication, that show separation from placebo within one to two weeks, a shift that has changed how she counsels patients on what to expect. Dr. Citrome adds that dextromethorphan is also a sigma-1 receptor agonist, a mechanism the field is still working to understand.

The conversation turns to psychedelics, which Dr. Harding says have generated enthusiasm ahead of the underlying science. She points to off-label ketamine use, emerging at-home compounds sometimes called neuroplastogens, and a recent educational poll in which more than sixty percent of clinician respondents incorrectly attributed psychedelics' mechanism to NMDA receptor antagonism. She references the STAR*D trial's declining response rates across successive treatment steps as evidence the field still underestimates how difficult depression treatment can be, and raises open questions about redosing criteria and monitoring for newer agents. Dr. Citrome asks whether a therapeutic effect could be separated from the psychedelic experience, and how much supervised time redosing would require.

Thank you for watching this Psychiatric Times series on major depressive disorder. Please subscribe to our eNewsletter for information on upcoming video series.


Related to this article